On Nov 02, major Wall Street analysts update their ratings for $Regeneron Pharmaceuticals (REGN.US)$, with price targets ranging from $800 to $1,195.
Morgan Stanley analyst Terence Flynn maintains with a buy rating, and maintains the target price at $1,184.
BofA Securities analyst Alec Stranahan maintains with a sell rating, and adjusts the target price from $805 to $800.
Barclays analyst Carter Gould maintains with a buy rating, and adjusts the target price from $1,080 to $1,065.
UBS analyst Colin Bristow maintains with a buy rating, and adjusts the target price from $1,251 to $1,130.
Evercore analyst Cory Kasimov maintains with a buy rating, and maintains the target price at $1,170.
Furthermore, according to the comprehensive report, the opinions of $Regeneron Pharmaceuticals (REGN.US)$'s main analysts recently are as follows:
Regeneron's Q3 financial results surpassed expectations marginally in terms of revenue and more significantly in earnings per share. Nevertheless, this was eclipsed by the performance of the Eylea franchise. Concerns have been raised about the future of the Eylea franchise due to the impending introduction of a biosimilar version by a competitor. These concerns encompass not only the anticipated faster erosion of the standard dose's market share, which may be underestimated by the market, but also potential negative effects on the higher dose variant.
Recent pressures on Regeneron shares are seen as excessive, according to analysts. This sentiment follows reactions to developments with Pavblu and a less than favorable Q4 outlook for Eylea HD, coupled with unclear projections regarding Eylea's future growth.
The decline in Regeneron's stock value following Q3 earnings was somewhat unexpected, as it was presumed that the near- and long-term consensus estimates for the optho franchise were overly optimistic. Nevertheless, it is believed that Regeneron's intrinsic fair value is substantially higher than the current share price.
Regeneron's recent quarterly financials aligned with optimistic revenue projections and surpassed expectations on earnings growth. However, the company's stock continues to encounter challenges stemming from its Eylea franchise and the looming threat of biosimilar competitors. The anticipated impact of a biosimilar by a competing company is still uncertain, but the initial response suggests it may not be as significant as feared, particularly given the tepid reception of other similar biosimilars in the market. The market's reaction to the pace at which patients are transitioning to Eylea HD has further pressured the stock's performance.
Here are the latest investment ratings and price targets for $Regeneron Pharmaceuticals (REGN.US)$ from 9 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.